Literature DB >> 22028325

p53-responsive miR-194 inhibits thrombospondin-1 and promotes angiogenesis in colon cancers.

Prema Sundaram1, Stacy Hultine, Lauren M Smith, Michael Dews, Jamie L Fox, Dauren Biyashev, Janell M Schelter, Qihong Huang, Michele A Cleary, Olga V Volpert, Andrei Thomas-Tikhonenko.   

Abstract

Thrombospondin-1 (TSP-1) is an endogenous inhibitor of angiogenesis encoded by the THBS1 gene, whose promoter is activated by p53. In advanced colorectal cancers (CRC), its expression is sustained or even slightly increased despite frequent loss of p53. Here, we determined that in HCT116 CRC cells, p53 activates the THBS1 primary transcript, but fails to boost THBS1 mRNA or protein levels, implying posttranscriptional regulation by microRNAs (miRNA). In a global miRNA gain-of-function screen done in the Dicer-deficient HCT116 variant, several miRNAs negatively regulated THBS1 mRNA and protein levels, one of them being miR-194. Notably, in agreement with published data, p53 upregulated miR-194 expression in THBS1 retrovirus-transduced HCT116 cells, leading to decreased TSP-1 levels. This negative effect was mediated by a single miR-194 complementary site in the THBS1 3'-untranslated region, and its elimination resulted in TSP-1 reactivation, impaired angiogenesis in Matrigel plugs, and reduced growth of HCT116 xenografts. Conversely, transient overexpression of miR-194 in HCT116/THBS1 cells boosted Matrigel angiogenesis, and its stable overexpression in Ras-induced murine colon carcinomas increased microvascular densities and vessel sizes. Although the overall contribution of miR-194 to neoplastic growth is context dependent, p53-induced activation of this GI tract-specific miRNA during ischemia could promote angiogenesis and facilitate tissue repair.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22028325      PMCID: PMC3242824          DOI: 10.1158/0008-5472.CAN-11-1124

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  49 in total

1.  PTEN controls tumor-induced angiogenesis.

Authors:  S Wen; J Stolarov; M P Myers; J D Su; M H Wigler; N K Tonks; D L Durden
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-27       Impact factor: 11.205

2.  Thrombospondin-1 and -2 in node-negative breast cancer: correlation with angiogenic factors, p53, cathepsin D, hormone receptors and prognosis.

Authors:  G Gasparini; M Toi; E Biganzoli; R Dittadi; M Fanelli; A Morabito; P Boracchi; M Gion
Journal:  Oncology       Date:  2001       Impact factor: 2.935

3.  Ras modulates Myc activity to repress thrombospondin-1 expression and increase tumor angiogenesis.

Authors:  Randolph S Watnick; Yi-Ning Cheng; Annapoorni Rangarajan; Tan A Ince; Robert A Weinberg
Journal:  Cancer Cell       Date:  2003-03       Impact factor: 31.743

4.  Activation of the myc oncoprotein leads to increased turnover of thrombospondin-1 mRNA.

Authors:  A Janz; C Sevignani; K Kenyon; C V Ngo; A Thomas-Tikhonenko
Journal:  Nucleic Acids Res       Date:  2000-06-01       Impact factor: 16.971

5.  Signals leading to apoptosis-dependent inhibition of neovascularization by thrombospondin-1.

Authors:  B Jiménez; O V Volpert; S E Crawford; M Febbraio; R L Silverstein; N Bouck
Journal:  Nat Med       Date:  2000-01       Impact factor: 53.440

6.  Thrombospondin-1 expression in patients with pathologic stage T3 prostate cancer undergoing radical prostatectomy: association with p53 alterations, tumor angiogenesis, and tumor progression.

Authors:  Gary D Grossfeld; Peter R Carroll; Neil Lindeman; Maxwell Meng; Susan Groshen; An Chen Feng; Debra Hawes; Richard J Cote
Journal:  Urology       Date:  2002-01       Impact factor: 2.649

7.  Opposing effects of hypoxia on expression of the angiogenic inhibitor thrombospondin 1 and the angiogenic inducer vascular endothelial growth factor.

Authors:  K R Laderoute; R M Alarcon; M D Brody; J M Calaoagan; E Y Chen; A M Knapp; Z Yun; N C Denko; A J Giaccia
Journal:  Clin Cancer Res       Date:  2000-07       Impact factor: 12.531

8.  Smad4/DPC4-mediated tumor suppression through suppression of angiogenesis.

Authors:  I Schwarte-Waldhoff; O V Volpert; N P Bouck; B Sipos; S A Hahn; S Klein-Scory; J Lüttges; G Klöppel; U Graeven; C Eilert-Micus; A Hintelmann; W Schmiegel
Journal:  Proc Natl Acad Sci U S A       Date:  2000-08-15       Impact factor: 11.205

9.  Thrombospondin-1 inhibits VEGF levels in the ovary directly by binding and internalization via the low density lipoprotein receptor-related protein-1 (LRP-1).

Authors:  James Greenaway; Jack Lawler; Roger Moorehead; Paul Bornstein; Jonathan Lamarre; Jim Petrik
Journal:  J Cell Physiol       Date:  2007-03       Impact factor: 6.384

10.  Thrombospondin-1 suppresses spontaneous tumor growth and inhibits activation of matrix metalloproteinase-9 and mobilization of vascular endothelial growth factor.

Authors:  J C Rodriguez-Manzaneque; T F Lane; M A Ortega; R O Hynes; J Lawler; M L Iruela-Arispe
Journal:  Proc Natl Acad Sci U S A       Date:  2001-10-16       Impact factor: 11.205

View more
  62 in total

1.  Multiple microRNAs derived from chemically synthesized precursors regulate thrombospondin 1 expression.

Authors:  Afzal M Dogar; Giuseppe Semplicio; Boris Guennewig; Jonathan Hall
Journal:  Nucleic Acid Ther       Date:  2014-01-20       Impact factor: 5.486

2.  MiR-122-5p inhibits cell migration and invasion in gastric cancer by down-regulating DUSP4.

Authors:  Xiaofeng Xu; Feng Gao; Jianjiang Wang; Lan Tao; Jinsong Ye; Li Ding; Wei Ji; Xing Chen
Journal:  Cancer Biol Ther       Date:  2018-03-06       Impact factor: 4.742

Review 3.  Invoking the power of thrombospondins: regulation of thrombospondins expression.

Authors:  Olga Stenina-Adognravi
Journal:  Matrix Biol       Date:  2014-02-25       Impact factor: 11.583

Review 4.  MicroRNAs in colorectal cancer: role in metastasis and clinical perspectives.

Authors:  Shan Muhammad; Kavanjit Kaur; Rui Huang; Qian Zhang; Paviter Kaur; Hamza Obaid Yazdani; Muhammad Umar Bilal; Jiang Zheng; Liu Zheng; Xi-Shan Wang
Journal:  World J Gastroenterol       Date:  2014-12-07       Impact factor: 5.742

5.  Targeting of TGFβ signature and its essential component CTGF by miR-18 correlates with improved survival in glioblastoma.

Authors:  Jamie L Fox; Michael Dews; Andy J Minn; Andrei Thomas-Tikhonenko
Journal:  RNA       Date:  2012-12-18       Impact factor: 4.942

6.  MicroRNA-194 inhibits the epithelial-mesenchymal transition in gastric cancer cells by targeting FoxM1.

Authors:  Zhenjun Li; Xiaojiang Ying; Hongliang Chen; Pingjiang Ye; Yi Shen; Weihuo Pan; Lihua Zhang
Journal:  Dig Dis Sci       Date:  2014-04-19       Impact factor: 3.199

7.  MicroRNAs responsive to Aggregatibacter actinomycetemcomitans and Porphyromonas gingivalis LPS modulate expression of genes regulating innate immunity in human macrophages.

Authors:  Afsar R Naqvi; Jezrom B Fordham; Asma Khan; Salvador Nares
Journal:  Innate Immun       Date:  2013-09-23       Impact factor: 2.680

Review 8.  MYC and the art of microRNA maintenance.

Authors:  James N Psathas; Andrei Thomas-Tikhonenko
Journal:  Cold Spring Harb Perspect Med       Date:  2014-04-15       Impact factor: 6.915

9.  Repigmentation of Human Vitiligo Skin by NBUVB Is Controlled by Transcription of GLI1 and Activation of the β-Catenin Pathway in the Hair Follicle Bulge Stem Cells.

Authors:  Nathaniel B Goldstein; Maranke I Koster; Kenneth L Jones; Bifeng Gao; Laura G Hoaglin; Steven E Robinson; Michael J Wright; Smaranda I Birlea; Abigail Luman; Karoline A Lambert; Yiqun G Shellman; Mayumi Fujita; William A Robinson; Dennis R Roop; David A Norris; Stanca A Birlea
Journal:  J Invest Dermatol       Date:  2017-10-17       Impact factor: 8.551

10.  Masking epistasis between MYC and TGF-β pathways in antiangiogenesis-mediated colon cancer suppression.

Authors:  Michael Dews; Grace S Tan; Stacy Hultine; Pichai Raman; Jaewoo Choi; Elizabeth K Duperret; Jack Lawler; Adam Bass; Andrei Thomas-Tikhonenko
Journal:  J Natl Cancer Inst       Date:  2014-03-13       Impact factor: 13.506

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.